drug

INCAGN02390

1 story · latest Aug 17, 2026

Status: Investigational
Trials: 2 registered trials in coverage

Relationships

Developed by Incyte Corporation

Timeline

Incyte posts results for Phase 1/2 anti-PD-1, LAG-3, TIM-3 combo trial in advanced malignancies

Aug 17Trial updateINCAGN02385 INCAGN02390

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.